THE HEART OF THE MATTER

Neovasc is a specialty medical device company that develops, manufactures and markets products for the cardiovascular marketplace. The company is focused on the development of minimally-invasive treatments for two of the most vexing challenges in cardiology today; refractory angina and mitral regurgitation. We believe there is tremendous potential in addressing these hard-to-treat conditions.

Neovasc is a publicly-traded company on both the NASDAQ and Toronto stock exchanges.

 

NVCN

NASDAQ

TORONTO (TSX)

Neovasc@

H.C. Wainwright Conference
President and CEO Fred Colen presentation
from Tuesday, September 13

register here >

Q2 2022 Financial Reports

View our Q2 financial statement,
management discussion & analysis,
and press release.

View Financial Reports